Potential neuroprotective effects of continuous topiramate therapy in the developing brain

Epilepsy Behav. 2011 Apr;20(4):597-601. doi: 10.1016/j.yebeh.2010.12.011. Epub 2011 Mar 30.

Abstract

Because antiepileptic drug therapy is usually given chronically with resulting concerns about long-term neurotoxicity, and because short-term topiramate (TPM) therapy has been reported to be neuroprotective against the effects of acute hypoxia, we investigated the long-term effects of continuous TPM therapy during early stages of development. Four groups of rat pups were studied: two sham manipulated normoxia groups and two acute hypoxia groups (at postnatal day [P] 10 down to 4% O(2)), each injected intraperitoneally daily with either vehicle or TPM (30 mg/kg) from P0 to P21. TPM therapy prevented hypoxia-induced long-term (P81) memory impairment (Morris water maze) as well as aggressivity (handling test). The hypoxia group receiving TPM also showed a trend toward reduced CA1 hippocampal cell loss. The aforementioned TPM therapy had no long-term deleterious effects on memory, hyperactivity, or CA1 cell counts in the TPM normoxia group as compared with normal controls.

MeSH terms

  • Age Factors
  • Analysis of Variance
  • Animals
  • Animals, Newborn
  • Brain / drug effects*
  • Brain / growth & development*
  • Disease Models, Animal
  • Exploratory Behavior / drug effects
  • Female
  • Fructose / analogs & derivatives*
  • Fructose / therapeutic use
  • Hypoxia / complications
  • Hypoxia / drug therapy
  • Hypoxia / pathology
  • Longitudinal Studies
  • Male
  • Maze Learning / drug effects
  • Memory Disorders / drug therapy*
  • Memory Disorders / etiology
  • Memory Disorders / pathology*
  • Neuroprotective Agents / therapeutic use*
  • Rats
  • Rats, Sprague-Dawley
  • Topiramate

Substances

  • Neuroprotective Agents
  • Topiramate
  • Fructose